Elite in Gallbladder Adenocarcinoma

Dr. Ghassan K. Abou-Alfa

Oncology
Memorial Solid Tumor Group
1275 York Ave, 
New York, NY 
Offers Telehealth
Elite in Gallbladder Adenocarcinoma
Memorial Solid Tumor Group
1275 York Ave, 
New York, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Ghassan Abou-Alfa is an Oncologist in New York, New York. Dr. Abou-Alfa is rated as an Elite provider by MediFind in the treatment of Gallbladder Adenocarcinoma. His top areas of expertise are Liver Cancer, Cholangiocarcinoma (Bile Duct Cancer), Fibrolamellar Carcinoma, Liver Embolization, and Pancreaticoduodenectomy.

His clinical research consists of co-authoring 280 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 4 articles and participated in 2 clinical trials in the study of Gallbladder Adenocarcinoma.

Specialties
Oncology
Licenses
Internal Medicine in NY
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital District Physicians Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health First
  • HMO
  • POS
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
MVP Health
  • EPO
  • PPO
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 16 Less Insurance Carriers -

Locations

MEMORIAL SOLID TUMOR GROUP
1275 York Ave, New York, NY 10065
Other Locations
MEMORIAL SOLID TUMOR GROUP
160 E 53rd St, New York, NY 10022

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase II Randomized Placebo-Controlled Study Investigating The Combination Of YIV-906 And Sorafenib (Nexavar®) In HBV (+) Patients With Advanced Hepatocellular Carcinoma
A Phase II Randomized Placebo-Controlled Study Investigating The Combination Of YIV-906 And Sorafenib (Nexavar®) In HBV (+) Patients With Advanced Hepatocellular Carcinoma
Enrollment Status: Completed
Publish Date: April 13, 2025
Intervention Type: Drug
Study Drugs: YIV-906, Sorafenib
Study Phase: Phase 2
A Phase 1 Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody as Monotherapy and in Combination With AGEN2034 (Balstilimab), an Anti-PD-1 Monoclonal Antibody, in Subjects With Advanced Cancer
A Phase 1 Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody as Monotherapy and in Combination With AGEN2034 (Balstilimab), an Anti-PD-1 Monoclonal Antibody, in Subjects With Advanced Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 06, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase 2, Open-label, Multicenter Study to Investigate the Efficacy, Safety, and Pharmacokinetics of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Patients With Previously Treated Hepatocellular Unresectable Carcinoma
A Phase 2, Open-label, Multicenter Study to Investigate the Efficacy, Safety, and Pharmacokinetics of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Patients With Previously Treated Hepatocellular Unresectable Carcinoma
Enrollment Status: Completed
Publish Date: October 26, 2024
Intervention Type: Drug
Study Drug: Tislelizumab
Study Phase: Phase 2
A Randomized Phase 2 Study of Atezolizumab in Combination With Cobimetinib Versus Atezolizumab Monotherapy in Participants With Unresectable Cholangiocarcinoma
A Randomized Phase 2 Study of Atezolizumab in Combination With Cobimetinib Versus Atezolizumab Monotherapy in Participants With Unresectable Cholangiocarcinoma
Enrollment Status: Completed
Publish Date: April 05, 2024
Intervention Type: Procedure, Drug
Study Drugs: Atezolizumab, Cobimetinib
Study Phase: Phase 2
A Randomized Study of Intrabucally Administered Electromagnetic Fields Versus Placebo for Patients With Child-Pugh A or B With Advanced Hepatocellular Carcinoma
A Randomized Study of Intrabucally Administered Electromagnetic Fields Versus Placebo for Patients With Child-Pugh A or B With Advanced Hepatocellular Carcinoma
Enrollment Status: Unknown
Publish Date: June 28, 2023
Intervention Type: Device
Study Phase: Phase 2/Phase 3
An Open-label Phase I Study to Evaluate the Safety, Tolerability and Efficacy of SynOV1.1 Recombinant Oncolytic Adenovirus Injection as Monotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
An Open-label Phase I Study to Evaluate the Safety, Tolerability and Efficacy of SynOV1.1 Recombinant Oncolytic Adenovirus Injection as Monotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
Enrollment Status: Unknown
Publish Date: February 02, 2023
Intervention Type: Biological
Study Drugs: SynOV1.1, Atezolizumab
Study Phase: Phase 1
Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
Enrollment Status: Completed
Publish Date: August 04, 2022
Intervention Type: Other, Drug
Study Drugs: Doxorubicin Hydrochloride, Sorafenib Tosylate
Study Phase: Phase 3
A Phase 1, Open-Label, Dose-Escalation and Expansion, Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
A Phase 1, Open-Label, Dose-Escalation and Expansion, Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
Enrollment Status: Terminated
Publish Date: July 15, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1B, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma
A Phase 1B, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma
Enrollment Status: Terminated
Publish Date: February 07, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 8 Less Clinical Trials

280 Total Publications

Clinical Utility and Prognostic Implications of Circulating Cell-Free DNA in Biliary Tract Cancer.
Clinical Utility and Prognostic Implications of Circulating Cell-Free DNA in Biliary Tract Cancer.
Journal: JCO precision oncology
Published: September 16, 2025
Similar Doctors
Elite in Gallbladder Adenocarcinoma
Dr. Eileen M. O'reilly
Oncology
Elite in Gallbladder Adenocarcinoma
Dr. Eileen M. O'reilly
Oncology

Memorial Solid Tumor Group

160 E 53rd St, 
New York, NY 
 (0.8 miles away)
212-639-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Eileen O'reilly is an Oncologist in New York, New York. Dr. O'reilly is rated as an Elite provider by MediFind in the treatment of Gallbladder Adenocarcinoma. Her top areas of expertise are Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Cholangiocarcinoma (Bile Duct Cancer), Pancreaticoduodenectomy, and Pancreatectomy.

Elite in Gallbladder Adenocarcinoma
Dr. James J. Harding
Hematology Oncology | Oncology
Elite in Gallbladder Adenocarcinoma
Dr. James J. Harding
Hematology Oncology | Oncology

Memorial Solid Tumor Group

1275 York Ave, 
New York, NY 
 (0.1 miles away)
212-639-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

James Harding is a Hematologist Oncology specialist and an Oncologist in New York, New York. Dr. Harding is rated as a Distinguished provider by MediFind in the treatment of Gallbladder Adenocarcinoma. His top areas of expertise are Cholangiocarcinoma (Bile Duct Cancer), Liver Cancer, Gallbladder Adenocarcinoma, Liver Embolization, and Hepatectomy.

Distinguished in Gallbladder Adenocarcinoma
Dr. Max W. Sung
Oncology | Hematology
Distinguished in Gallbladder Adenocarcinoma
Dr. Max W. Sung
Oncology | Hematology

Icahn School Of Medicine At Mount Sinai

5 E 98th St, Suite 6, 
New York, NY 
 (1.7 miles away)
212-241-4812
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Max Sung is an Oncologist and a Hematologist in New York, New York. Dr. Sung is rated as a Distinguished provider by MediFind in the treatment of Gallbladder Adenocarcinoma. His top areas of expertise are Fibrolamellar Carcinoma, Liver Cancer, Gallbladder Adenocarcinoma, and Gallbladder Cancer.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Abou-Alfa's expertise for a condition
ConditionClose
View All 20 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile